Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice

被引:15
作者
Huo, Yuqi [1 ]
Wan, Xin [1 ]
Ling, Tong [1 ]
Wu, Jie [1 ]
Wang, Zejun [1 ]
Meng, Shengli [1 ]
Shen, Shuo [1 ]
机构
[1] Wuhan Inst Biol Prod Co Ltd, Wuhan, Peoples R China
关键词
Norovirus; Sydney-2012-like strain; Immune response; Adjuvants; VIRUS-LIKE PARTICLES; GROUP ANTIGEN RECEPTORS; CAPSID PROTEIN FORMS; P-DOMAIN; NORWALK; STRAIN; CELLS; NOMENCLATURE; BINDS; RNA;
D O I
10.1016/j.molimm.2015.09.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The newly emerged Norovirus (NoV) Sydney 2012 strain has been sweeping all over the world, causing acute non-bacterial gastroenteritis in adults and children. Due to a lack of cell culture system, virus like particles (VLPs) has been assembled and used as vaccine candidates in preclinical and clinical studies. Expression of the major capsid protein of NoVs using recombinant baculovirus expression system in Sf9 cells leads to formation of VLPs that are morphologically and antigenically similar to true virions. In this study, VLPs were successfully produced using the VP1 of Sydney-2012-like strain and its immunogenicity was evaluated by different routes and its capability in inducing mucosal immune responses in the presence and absence of adjuvants in BALB/c mice. Administration of NoV VLPs in the presence of Al(OH)(3) or monophosphoryl lipid A (MPL-A) led to high titers of VLP-specific IgG antibodies. Administration of VLPs orally in the presence of cholera toxin subunit B (CTB) didn't enhance mucosa( immune response as less fecal IgA positive mice were observed when compared with those given VLPs only. Our study represents the first immunogenicity study of VLPs derived from current pandemic Sydney 2012 strain and which might have implications in the development of NoVs vaccine in china. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:367 / 372
页数:6
相关论文
共 28 条
[1]   Replication and packaging of Norwalk virus RNA in cultured mammalian cells [J].
Asanaka, M ;
Atmar, RL ;
Ruvolo, V ;
Crawford, SE ;
Neill, FH ;
Estes, MK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (29) :10327-10332
[2]   Norovirus Vaccine against Experimental Human Norwalk Virus Illness [J].
Atmar, Robert L. ;
Bernstein, David I. ;
Harro, Clayton D. ;
Al-Ibrahim, Mohamed S. ;
Chen, Wilbur H. ;
Ferreira, Jennifer ;
Estes, Mary K. ;
Graham, David Y. ;
Opekun, Antone R. ;
Richardson, Charles ;
Mendelman, Paul M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (23) :2178-2187
[3]   Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice [J].
Ball, JM ;
Hardy, ME ;
Atmar, RL ;
Conner, ME ;
Estes, MK .
JOURNAL OF VIROLOGY, 1998, 72 (02) :1345-1353
[4]   Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study [J].
Ball, JM ;
Graham, DY ;
Opekun, AR ;
Gilger, MA ;
Guerrero, RA ;
Estes, MK .
GASTROENTEROLOGY, 1999, 117 (01) :40-48
[5]   Characterization of capsid genes, expressed in the Baculovirus system, of three new genetically distinct strains of "Norwalk-Like viruses" [J].
Belliot, G ;
Noel, JS ;
Li, JF ;
Seto, Y ;
Humphrey, CD ;
Ando, T ;
Glass, RI ;
Monroe, SS .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (12) :4288-4295
[6]  
Bernstein D.I., 2014, Journal of Infectious Disease
[7]  
Blazevic V., 2015, J MED VIROL
[8]   Rapid Evolution of Pandemic Noroviruses of the GII.4 Lineage [J].
Bull, Rowena A. ;
Eden, John-Sebastian ;
Rawlinson, William D. ;
White, Peter A. .
PLOS PATHOGENS, 2010, 6 (03)
[9]   Norovirus P Particle Efficiently Elicits Innate, Humoral and Cellular Immunity [J].
Fang, Hao ;
Tan, Ming ;
Xia, Ming ;
Wang, Leyi ;
Jiang, Xi .
PLOS ONE, 2013, 8 (04)
[10]   Emergence of a New Norovirus GII.4 Variant and Changes in the Historical Biennial Pattern of Norovirus Outbreak Activity in Alberta, Canada, from 2008 to 2013 [J].
Hasing, Maria E. ;
Lee, Bonita E. ;
Preiksaitis, Jutta K. ;
Tellier, Raymond ;
Honish, Lance ;
Senthilselvan, Ambikaipakan ;
Pang, Xiaoli L. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (07) :2204-2211